At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 134 enrolled
Drug / intervention
OCV-501 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
In Brief
A Phase 2 clinical trial evaluating OCV-501 and Placebo for Acute Myeloid Leukemia. Completed, enrolled 134 participants across 14 sites in 3 countries.
Detailed Summary
To compare disease-free survival in patients 60 years or older with acute myeloid leukemia (AML) who are randomly assigned to receive either OCV-501 monotherapy or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesJapan, South Korea, Taiwan
CollaboratorsKorea Otsuka Pharmaceutical Co., Ltd.
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionNov 2017
TodayJul 2026
First PostedOct 14, 2013
Enrollment StartOct 1, 2013
Primary CompletionNov 16, 2017
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.7 years ago
Interventions
OCV-501drug
Placebodrug